MedTrace Logo

Patient Registry to Evaluate the Real-world Safety of Ruconest®

NCT03697187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2024-04-05

No results posted yet for this study

Summary

This is a prospective, real-world, observational patient registry for patients with HAE who are receiving treatment with Ruconest for HAE.

Conditions

Interventions

DRUG

rhC1INH

Recombinant human C1 inhibitor

Sponsors & Collaborators

  • US Hereditary Angioedema Association

    collaborator UNKNOWN

  • Pharming Technologies B.V.

    lead INDUSTRY

Principal Investigators

  • Anurag Relan, MD · Pharming Technologies BV

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2021-06-30
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697187 on ClinicalTrials.gov